ARIBIO-CO-LTD
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Streamlines Network and Security Operations by Utilizing Keysight’s Application Fusion Platform18.11.2025 14:00:00 CET | Press release
Armis' technology can now run on the Keysight Vision E1S network packet brokers using the open interface known as Application Fusion, empowering security teams to enhance efficiency, reduce infrastructure costs and strengthen their security posture Armis, the cyber exposure management & security company, and Keysight Technologies, Inc. (NYSE: KEYS) today announced that Armis’ cyber exposure management technology will now run directly on the Keysight Vision E1S network packet brokers, with additional models expected to support Application Fusion in the future. Through the Application Fusion interface, Armis’ technology can now run directly on the Keysight network packet brokers, combining network visibility with continuous cyber exposure management and security capabilities. By providing immediate, actionable insights across the entire network, without the need for additional hardware, security teams can respond to threats faster, proactively reduce risk and increase operational efficie
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis18.11.2025 14:00:00 CET | Press release
New method enables single cell discovery from archived tissue samples, expanding access to translational and clinical research Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraffin-embedded (FFPE) samples. By enabling whole transcriptome capture from archived tissues at single cell resolution, this innovation opens new possibilities for discovery in oncology, translational research, and precision medicine. The use of FFPE samples for single cell RNA sequencing (scRNA-seq) has traditionally been limited to profiling a predefined list of genes due to RNA degradation and fragmentation, reducing transcriptome coverage and discovery potential. Parse’s breakthrough overcomes these challenges with a novel split-pool combinatorial barcoding method that enables true transcriptome-wide scRNA-seq of FFPE-preserved tissues through its unique RNA captu
KP Labs and Frontgrade Gaisler Join Forces to Advance Fault-Tolerant Computing for Next-Generation Space Missions18.11.2025 14:00:00 CET | Press release
KP Labs, a European Leader in delivering autonomous systems for space applications and Frontgrade™ Gaisler Technologies, a leading provider of high-reliability electronic solutions for space and national security missions have signed a Memorandum of Understanding during the Space Tech Expo Europe in Bremen, Germany. The agreement establishes a framework for collaboration in developing and validating advanced on-board computing architectures designed to increase the autonomy and resilience of future space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118359687/en/ As satellite operators and mission designers increasingly rely on on-board data processing and autonomy, maintaining fault tolerance and reliability has become a critical priority. To meet these demands, modern spacecraft integrates radiation-hardened components and advanced FDIR (Fault Detection, Isolation and Recovery) systems that ensure stable oper
ACE Fiber uses Adtran’s Mosaic One Clarity AI solution for proactive assurance, faster resolution and fewer truck rolls18.11.2025 14:00:00 CET | Press release
News summary: Mississippi provider’s fiber expansion increased operational complexity, driving the need for quicker troubleshooting and fewer site visits With Adtran’s Mosaic One Clarity, built on its REAL AI platform, ACE Fiber is transforming operations to prevent issues and reduce costs Early results show up to 75% fewer tickets in the first month, cutting service calls and improving customer experiences Adtran today announced that ACE Fiber, the broadband subsidiary of Mississippi’s ACE Power, is using its Mosaic One Clarity solution, built on the REAL AI platform, to move from reactive troubleshooting to proactive assurance across ACE Fiber’s expanding network. Mosaic One Clarity consolidates network and in-home data, identifies likely root causes and provides guided actions that help teams resolve issues faster and avoid unnecessary site visits. By detecting early signs of fiber performance issues and showing which subscribers are affected, Mosaic One Clarity enables more right-f
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D18.11.2025 13:55:00 CET | Press release
In the United Arab Emirates, where cities like Abu Dhabi and Dubai consistently rank among the world's most forward-thinking, the Emirate of Sharjah, the country's cultural and knowledge capital, has decisively positioned itself as a premier hub for research and innovations in healthcare. This transformation is primarily driven by the Sharjah Research, Technology and Innovation Park (SPARK) formerly SRTIP, SRTI Park. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118121763/en/ SPARK Headquarters (SPARK HQ) (Photo: AETOSWire) This ambition was powerfully demonstrated during the recent "Sharjah Next: Healthcare" forum, which transcended a typical conference, evolving into a powerful statement of intent. It assembled a host of global healthcare luminaries, including Professor Sir Magdi Yacoub, a pioneer in cardiothoracic surgery; Professor Humaid Obaid Al-Shamsi, a leading Emirati oncologist; and Dr. Vladimir Ivkovic of Harv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom